MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced the
signing of a protein engineering agreement with a large bio-pharmaceutical
company. The non-exclusive license agreement covers the delivery of multiple
Slonomics(®)-based DNA libraries. The libraries will encode a broad range of
protein classes, excluding antibodies, and will be used by its partner for drug
discovery. MorphoSys will receive committed annual funding for the delivery of
libraries over the three-year lifetime of the agreement and stands to receive
milestone and royalty payments on each product emerging from the collaboration.
"This fourth alliance around the Slonomics technology further illustrates the
value of the platform," commented Dr. Simon Moroney, Chief Executive Officer of
MorphoSys AG. "Slonomics is a powerful method for making libraries of all types,
and this agreement exemplifies the commercial opportunity it creates for us
beyond the antibody field."
The Slonomics technology enables the precise construction of protein libraries
comprising defined mixtures of amino acids at pre-determined positions with
unprecedented speed. The technology provides a new and flexible approach to
generating optimized proteins. MorphoSys acquired Slonomics through Sloning
BioTechnology in October 2010.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®) and
arYla(®) are registered trademarks of MorphoSys. Ylanthia(®) and 100 billion
high potentials(TM) are trademarks of MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release:
http://hugin.info/130295/R/1588398/498515.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1588398]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.02.2012 - 01:30 Uhr
Sprache: Deutsch
News-ID 1086749
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 67 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology
"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
